



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61F 5/00	A1	(11) International Publication Number: WO 00/69376 (43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/US00/13703		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 18 May 2000 (18.05.00)		
(30) Priority Data: 60/134,672 18 May 1999 (18.05.99) US 09/571,080 15 May 2000 (15.05.00) US		
(71) Applicant: SILHOUETTE MEDICAL INC. [US/US]; 687 North Pastoria Drive, Sunnyvale, CA 94086 (US).		
(72) Inventor: EDWARDS, Stuart, D.; 658 Westbridge Drive, Portola Valley, CA 94028 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(74) Agent: SWERNOFSKY LAW GROUP; P.O. Box 390013, Mountain View, CA 94039-0013 (US).		
(54) Title: SURGICAL WEIGHT CONTROL DEVICE		
(57) Abstract		
This invention provides a method and system for the curative treatment of obesity. A first aspect of this invention is that it enables identification of the nerves responsible for the relaxation of the stomach muscles that occurs prior to and during eating. A second aspect of the invention is that it allows the physician to identify focal nerve sites in the stomach and upper duodenum that are associated with producing sensations of hunger and satiety. Nervous transmission from these sites can be modulated or blocked all together so as to minimize the sensation of hunger. A third aspect of this invention is that it allows a physician to shrink selected portions of the innermost oblique muscle and middle circular muscle layers of the stomach. This can be performed in a physician's office using local anesthesia. Shrinkage of these muscles produces a feeling of satiety that enhances the patient's efforts to restrict his caloric intake.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SURGICAL WEIGHT CONTROL DEVICE

Background of the Invention5 *1. Field of the Invention*

This invention relates to controlling obesity.

10 *2. Related Art*

Obesity is directly associated with a disorders such as osteoarthritis (especially in the hips) sciatica, varicose veins, thromboembolism, ventral and hiatal hernias, hypertension, insulin resistance and hyperinsulinemia. All of these conditions can be ameliorated by treatment of obesity, provided the weight loss is significant and enduring.

The known art of treating obesity includes behavioral strategies, various different pharmaceutical interventions and surgery.

20 One problem in the known art of behavioral strategies is patient compliance. Extremely high levels of patient compliance over a long period of time are required to produce a significant weight loss.

25 Problems in the known art of pharmaceutical intervention include drug dependence and side effects. Treatment with amphetamine analogs requires habitual use of an addictive drug to produce a significant weight loss. Treatment with drugs such as dextroamphetamine and fenfluramine is frequently associated with primary pulmonary hypertension and cardiac valve abnormalities. Drugs such as sibutramine cause a substantial increase in blood pressure in a large number of patients.

30

The known art of surgical treatment of obesity includes operative procedures such as end-to-end anastomosis of about 38 cm of proximal jejunum to 10 cm of terminal ileum and other variants of jejunoileal manipulation. While such procedures are extremely effective, the overall rates of surgical mortality and 5 associated hepatic dysfunction are so high that this treatment is only indicated for younger patients who are morbidly obese.

Accordingly, it would be advantageous to provide a method and system for treatment of obesity that produces reasonably rapid weight loss, long term results, 10 low surgical mortality, few side effects and can be performed under local anesthesia. This advantage is achieved is an embodiment of an invention in which a balloon bearing an array of electrodes is deployed in the stomach and upper duodenum. This device maps and ablates nerves in these tissues and causes shrinkage of stomach muscle by creating a pattern of thermal lesions. Weight control is achieved by 15 creating a sense of satiety in the patient. This can be achieved by direct modulation of nerves responsible for the sensation of hunger or by inhibiting the let-down reflex of the stomach muscles that serves as a precursor to digestion.

Summary of the Invention

20

This invention provides a method and system for the curative treatment of obesity.

A first aspect of this invention is that it enables identification of the 25 nerves responsible for the relaxation of the stomach muscles that occurs prior to and during eating. Relaxation and extension of these muscles allows the stomach to take in a greater quantity of food and facilitates the feeding process. In the event that impulses from the gastric cardia fail to transmit information to the vagus nerve and hindbrain, the muscular tone of the stomach will remain normal during a meal. The 30 result is early satiety and correspondingly, less food intake. In a preferred embodiment, this invention can be used to modulate these nerves in the gastric cardia

and inhibit the relaxation of stomach muscles, thereby creating a sensation of fullness more rapidly than would occur otherwise.

A second aspect of the invention is that it allows the physician to
5 identify focal nerve sites in the stomach and upper duodenum that are associated with producing sensations of hunger and satiety. Nervous transmission from these sites can be modulated or blocked all together so as to minimize the sensation of hunger.

A third aspect of this invention is that it allows a physician to shrink
10 selected portions of the innermost oblique muscle and middle circular muscle layers of the stomach. This can be performed in a physician's office using local anesthesia. Shrinkage of these muscles produces a feeling of satiety that enhances the patient's efforts to restrict his caloric intake.

15

Brief Description of the Drawings

Figure 1 is a block diagram of a first device used in a system for treatment of obesity.

20

Figure 2 is a block diagram of a second device used in a system for treatment of obesity.

Figure 3 is a block diagram of a control apparatus to be used with a first or second device in a system for treatment of obesity.

25

Figure 4 (comprising figures 4A and 4B) is a process flow diagram of a method for the treatment of obesity.

Detailed Description of the Preferred Embodiment

30

In the following description, a preferred embodiment of the invention is described with regard to preferred process steps and data structures. Those skilled in

the art would recognize, after perusal of this application, that embodiments of the invention can be implemented using circuitry or other structures adapted to particular process steps and data structures, and that implementation of the process steps and data structures described herein would not require undue experimentation or further 5 invention.

System Elements

Figure 1 is a block diagram of a first device used in a system for
10 treatment of obesity.

A system 100 includes a treatment element 110, a catheter 310 and a control apparatus 315. The treatment element 110 is mounted on the most distal end of the catheter 310 in such a way that the treatment element 110 and catheter 310 form one contiguous piece. This figure is restricted to the treatment element 110. The catheter 310 and control apparatus 315 are described in greater detail in figure 3.

The treatment element 110 includes a distal tip 111, a first balloon 115, a spacer 120, a second balloon 125, and a plurality of lumens 140 (not shown). Both 20 the first balloon 115 and second balloon 125 include a set of electrodes 135 and a set of thermocouples 136.

The distal tip 111 is composed of a long, relatively narrow tubular element composed of relatively stiff, biologically non-reactive plastic that is disposed 25 for insertion into the stomach and the portion of the duodenum immediately proximate to the stomach. In a preferred embodiment, the distal tip 111 is an extension of the catheter 310 (described supra).

The first balloon 115 is mounted between the distal tip 111 and the 30 spacer 120. In a preferred embodiment, the first balloon 115 is approximately three times as long as it is wide, with the long end running between the distal tip 111 and

the spacer 120. The walls of the first balloon 115 are comprised of mylar or a similar biologically non-reactive material that can be inflated with a variety of liquids such as saline, Ringers or water. In some embodiments, the first treatment balloon 115 includes micropores for delivery of liquid to a tissue. In these embodiments, 5 pharmacological agents such as irrigating fluids, antibiotics, anti-inflammatories, anti-spasmodics and anesthetics can be exuded from micropores in the balloon 115. Some of the lumens included in the plurality of lumens 130 are dedicated to inflation and deflation of the first balloon 115.

10 The electrodes 135 are distributed equidistant to each other in concentric rings along a longitudinal axis of the first treatment balloon 115. Each electrode 135 includes a thermocouple 136 so that the temperature of each electrode 135 can be monitored separately.

15 In a preferred embodiment, the electrodes 135 included in the first balloon 115 are disposed to deliver RF energy to portions of the duodenum that are generally proximate to the stomach. In other embodiments, the electrodes 135 may be disposed to deliver microwave, laser, ELF (extremely low frequency) or other therapeutic energies.

20 A spacer 120 lies between the first treatment balloon 115 and the second treatment balloon 125. In a preferred embodiment, the spacer 120 lies in the same plane as the distal tip 115 and is composed of relatively stiff material comparable to that of the distal tip 115 and catheter. Although the size of the spacer 25 120 may vary (for example, a spacer 120 used in a device to treat children will be smaller than a spacer 120 used in a device to treat adults), the relative proportions between the spacer 120 and the size of the first and second treatment balloons 115 and 125 do not vary.

30 In a preferred embodiment, the spacer 120 separates the first treatment balloon 115 and second treatment balloon 125, thereby allowing two separate and

distinct areas (that is, areas in the duodenum and stomach) to be treated individually and simultaneously.

The second treatment balloon 125 is mounted between the spacer 120 and the catheter 310 and control apparatus 315. In a preferred embodiment, the shape of the second balloon 125 is similar to a bisected sphere with the center of the spherical side coupled to the spacer 120 and the flat portion coupled to the catheter 310. The widest portion of the second treatment balloon 125 is approximately three times wider than the width of the first treatment balloon 120. In a preferred embodiment, the second treatment balloon 125 is disposed in a stomach while the first treatment balloon 115 is disposed in a duodenum.

Similar to the first treatment balloon 115, the second treatment balloon 125 is comprised of mylar or other similar biologically non-reactive material that can be inflated with air or a variety of liquids such as saline, Ringers or water. In some embodiments of the invention, the second treatment balloon 125 includes micropores for delivery of a liquid to a tissue. In these embodiments, pharmacological agents such as irrigating fluids, antibiotics, anti-inflammatories, anti-spasmodics and anesthetics may be exuded from micropores in the balloon 125. Some of the lumens included in the plurality of lumens 140 are dedicated to inflation and deflation of the second balloon 125.

The electrodes 135 are distributed equidistant to each other in concentric rings along a spherical portion of the second treatment balloon 115. There are no electrodes 135 on the proximal side of the second treatment balloon 125 (that is, the portion of the balloon 125 coupled to the catheter 310 and control apparatus 315). Each electrode 135 includes a thermocouple 136 so that the temperature of each electrode 135 can be monitored separately.

In a preferred embodiment, the electrodes 135 included in the second balloon 125 are disposed to deliver RF energy to portions of the stomach. In other

embodiments, the electrodes 135 may be disposed to deliver microwave, laser, ELF (extremely low frequency) or other therapeutic energies.

The lumens 140 are disposed to control the electrodes 135, transmit the
5 RF energy or channel the fluids to the first treatment balloon 115 and the second treatment balloon 125. All of the lumens 140 traverse the entire length of the catheter 310 and terminate at the treatment element 110 at an electrode 135, a thermocouple 136, the interior of a first treatment balloon 115 or the interior of a second treatment balloon 125.

10

Figure 2 is a block diagram of a second device used in a system for treatment of obesity.

A system 200 includes a treatment element 210, a catheter 310 and a
15 control apparatus 315. The treatment element 210 is mounted on the most distal end of the catheter 310 in such a way that the treatment element 210 and catheter 310 form one contiguous piece. Figure 2 is restricted to the treatment element 210. The catheter 310 and control apparatus 315 are described in greater detail in figure 3.

The treatment element 210 includes a distal tip 211, a plurality of struts
20 215, a balloon 220 and a plurality of lumens 240 (not shown). The set of struts 215 includes a set of electrodes 235 and a set of thermocouples 236.

The distal tip 211 is composed of a long, relatively narrow tubular
element composed of relatively stiff, biologically non-reactive plastic that is disposed
25 for insertion into the stomach and the portion of the duodenum immediately proximate to the stomach. In a preferred embodiment, the distal tip 211 is an extension of the catheter 310 (described supra).

The plurality of struts 215 is mounted between the distal tip 211 and
30 catheter so that the distal end of each strut terminates at the proximal end of the distal tip 211 and the proximal end of each strut terminates at the catheter 310. The length

of struts included in the plurality of struts 215 between the distal tip 211 and catheter is between three and four times as long as the distal tip 211. In a preferred embodiment, there are between ten and twenty individual struts 215. Other embodiments may include different numbers of struts 215.

5

Each strut in the plurality of struts 215 includes at least one electrode from the plurality of electrodes 235. Each electrode 235 includes a thermocouple 236 so that the temperature of each electrode 235 can be monitored separately. The electrodes 235 are slightly arced needle electrodes, mounted in such a way as to curve away from the distal tip 211. Each electrode 235 is staggered along the length of the strut 215 relative to the other electrodes 235 so that taken together, the plurality of electrodes 235 are evenly distributed at different lengths along the struts 215.

In a preferred embodiment, the electrodes 235 are disposed to deliver RF energy to the stomach and portions of the duodenum that are generally proximate to the stomach. In other embodiments, the electrodes 235 may be disposed to deliver microwave, laser, ELF (extremely low frequency) or other therapeutic energies. The electrodes 235 may also be disposed to deliver a variety of substances such as cooling liquids and pharmaceutical agents.

20

In addition to the struts 215, a balloon 220 is also mounted between the distal tip 215 and the catheter 310. The balloon 220 is coupled in such a way that the exterior portion of the balloon 220 is encircled by the set of struts 215. Inflation of the balloon 220 causes the electrodes 235 to be brought into closer proximity to the targeted tissue in the duodenum and stomach. In a preferred embodiment, the balloon 220 can be inflated with a variety of cooling liquids such as saline, Ringers or water. In other embodiments, the balloon 220 includes a plurality of micropores. In such embodiments, pharmacological agents such as irrigating fluids, antibiotics, anti-inflammatories, anti-spasmodics and anesthetics can be exuded from micropores in the balloon. Some of the lumens included in the plurality of lumens 230 are dedicated to inflation and deflation of the balloon 220.

The lumens 240 are disposed to control the electrodes 235, transmit the RF energy or channel the fluids to the treatment balloon 220. All of the lumens 130 traverse the entire length of the catheter 310 and terminate at the treatment element 210 either at an electrode 235, a thermocouple 236 or in the interior of a treatment 5 balloon 220.

Figure 3 is a block diagram of a control apparatus to be used with a first or second device in a system for treatment of obesity.

10 A system 300 is used to control the delivery of energy, cooling fluids and pharmaceutical agents through the first and second devices described infra.

15 A system 300 includes a catheter 310 and control mechanism 315. The control mechanism 315 houses all the elements needed to control the treatment element 110 or treatment element 210. As such, the control mechanism 315 includes a handgrip 320, an electrode manipulation element 325, a therapeutic energy connector 330, an inflation control port 335 and a deflation control port 340.

20 The catheter 310 is coupled on the distal end to treatment element 110 or treatment element 210 and coupled on the proximal end to the control mechanism 315. The catheter 310 is comprised of biologically non-reactive material and is sufficiently flexible so as to be introduced through the oral cavity, threaded through an esophagus and into a stomach. The overall length of the catheter may vary, but is responsive to the distance from a mouth to a duodenum. In alternative embodiments, 25 the overall length of the catheter 310 may be responsive to the distance between a surgical incision and a duodenum. The catheter 310 is disposed to house lumens 140 or lumens 240 (not shown), which traverse the entire length of the catheter 310.

30 The electrode manipulation element 325 is mounted on the most distal portion of the control apparatus 325 immediately adjacent and contiguous with the handgrip 320. The electrode manipulation element 325 is coupled to proximal end of

some of the lumens 140 or lumens 240. As such, the electrode manipulation element 325 can be used to activate or deactivate electrodes included in systems 100 or 200. These electrodes can be controlled either individually or in combination. Activation or deactivation is also responsive to feedback from thermocouples 136 or 236 or to 5 the physician's professional judgment.

The therapeutic energy connector 330 is mounted on the most proximal end of the control apparatus 325. As such, it is coupled to the most proximal end of some of the lumens 140 or 240 that traverse the interior of the catheter 310 and 10 handgrip 320. In a preferred embodiment, the therapeutic energy connector 330 is disposed to be connected to an RF generator. In other embodiments, the therapeutic energy connector 330 can be disposed to be connected to a generator of microwaves, infrared, ELF, laser or other therapeutic energy.

15 The inflation control port 335 is mounted immediately between the therapeutic energy connector 330 and the deflation control port 340 on the top portion of the control apparatus 325. The proximal end of some of the lumens 140 or lumens 240 terminate at the inflation control port 325.

20 In a preferred embodiment, the inflation control port 335 is disposed to be coupled to a source of cooling liquids or pharmaceutical agents in liquid form. Examples of substances that can be introduced through the fluid input port 335 include sterile saline, sterile water, Ringers, antibiotic solutions, local anesthetics and other agents.

25 Deflation control port 340 is immediately adjacent to the inflation control port 335. The interior portion of the deflation control port 340 is coupled to some of the lumens 140 or 240 in such a way that fluids used to inflate the first treatment balloon 115, second treatment balloon 125 or treatment balloon 220 can be 30 suctioned away and the balloons deflated.

In a preferred embodiment the fluid output port 340 may be coupled to a pump or other apparatus to remove fluids. Pumping may occur in response to liquids entering the inflation control port 335, so as to achieve a continuously circulating stream of cooling liquid.

Method of Use

Figure 4 is a process flow diagram of a method for the treatment of obesity.

5 A method 400 is performed by a system 100 or 200 and a system 300.

At a flow point 400, the therapeutic energy connector 330 is coupled to an RF generator. In other embodiments, the therapeutic energy connector 330 is coupled to an RF generator. In other embodiments, the therapeutic energy connector 10 330 is coupled to other sources of therapeutic energy such as laser, ELF, infrared or microwave.

At a step 405, suction, inflation or fluid infusion apparatus is coupled to the inflation control port 235 and deflation control port 340 so that the balloons 115 15 and 125 or 220 may be inflated with a continuously circulating stream of liquids or pharmacological agents. The type of fluid used to inflate the balloons is responsive to the professional judgment of the physician.

At a step 410, the visualization apparatus, such as a flouroscope, an 20 endoscope, a display screen or other visualization device is turned on and positioned so as to be used in a patient. The choice of visualization apparatus and method of use are responsive to judgments by medical personnel. If other equipment is needed (for example, monitoring equipment for patient vital signs), the equipment is prepared at this time.

25 At a step 415, the patient is positioned on a treatment table, in an appropriate position. Depending upon the professional judgment of the physician, varying degrees of local or general anesthesia may be induced.

At a step 420, the treatment element 110 or 210 is inserted through the 30 oral cavity, distal tip first. Visualization apparatus is used to track the treatment element 110 or 210 as it is threaded through the esophagus. Upon entry into the

stomach, the collar of helvetius, middle circular stomach muscle layers, longitudinal muscle of duodenum, circular muscle of the duodenum, pyloris and gastric cardia and other associated structures are identified. Regardless whether the first or second device is used, all of the treatment balloons associated with a particular device are
5 deflated to facilitate inflation.

At a step 425, the tissues targeted for treatment are identified and the associated nerves are mapped. The treatment element 110 or 210 is positioned so as to be relatively proximate to a targeted area.
10

At a step 430, the inflation control port 335, deflation control port 340 and equipment associated therewith are manipulated and the balloons associated with treatment elements 110 or 210 are inflated from a continuously circulating stream of cooling fluid such as saline, water, Ringers or other liquids. Inflation of the balloon(s)
15 115 and/or 125, or balloon 220 brings electrodes 135 or electrodes 235 in contact with the targeted tissues. If treatment element 110 is used, balloons 115 and 125 may be inflated dependently or independently of each other. This circulating cooling liquid lowers the relative temperature of the targeted tissue and prevents collateral thermal damage that might otherwise occur. If a microporous balloon(s) is used, the
20 balloon may also be inflated with pharmaceutical agents such as antibiotics, antacids, anti-inflammatories and other drugs, including those that might be useful in pretreating the targeted areas. The choice of cooling liquid(s) and pharmaceutical agent(s) are responsive to the professional judgment of the physician.

25 At a step 435, the electrode manipulation element 325 is activated so as to select which electrodes included in the plurality of electrodes 135 or 235 are appropriate for treatment and to cause a release of energy from these selected electrodes. The duration and frequency of energy are responsive to judgments by medical personnel. This release of energy creates a pattern of lesions in the tissues of
30 the stomach, duodenum and gastric cardia. Depending upon the professional judgment of the physician, energy may be directed toward nerves in the gastric cardia

so as to prevent relaxation of stomach muscles. In other embodiments, treatment may include direct modulation of nerves associated with the sensation of satiety or tightening of tissues in portions of the stomach and duodenum that are proximate to each other. This step may be repeated in other portions of the stomach in a manner 5 that is responsive to the professional judgment of the physician. In some embodiments of the invention, the second treatment balloon 125 includes micropores for delivery of liquid to a tissue.

In a preferred embodiment, the temperature increase that accompanies 10 the release of energy from each electrode 135 or 235 is monitored by the thermocouple 136 or 236 associated with that particular electrode in such a way that if the temperature approaches a preset limit, then that particular electrode is automatically deactivated.

15 At a step 440, the inflation control port 345 is manipulated so as to stop the flow of liquids into the system 100 or system 200. This causes the balloons associated with treatment elements 110 or 210 to deflate.

At a step 445, the treatment element 110 or 210 is withdrawn from the 20 stomach via the oral cavity. In embodiments that involve surgical introduction of the treatment element 110 or 210, the element is removed through the surgical incision. Appropriate follow-up care is responsive to the professional judgment of the physician.

Alternative Embodiments

Although preferred embodiments are disclosed herein, many variations are possible which remain within the concept, scope, and spirit of the invention, and
5 these variations would become clear to those skilled in the art after perusal of this application.

Claims

1. An apparatus for treatment of obesity including
a catheter capable of being disposed in a region of the body of a patient,
5 said region being located proximate to a junction between the stomach and the
duodenum;
a first balloon;
a second balloon;
a plurality of electrodes embedded in the outer surfaces of said first
10 balloon and said second balloon; and
a plurality of lumens.
2. An apparatus as in claim 1, wherein said catheter can be
disposed in a gastric cardia, greater curvature, collar of helvetius, middle circular
15 stomach muscle layers, longitudinal and circular muscles of the duodenem, the
pylorus and other structures proximate to the stomach.
3. An apparatus as in claim 1, wherein said catheter is disposed to
be inserted orally or through a surgical opening.
20
4. An apparatus as in claim 1, wherein the length of said catheter is
responsive to the relative size or age of the patient and the manner of insertion.
5. An apparatus as in claim 1, wherein the first treatment balloon is
comprised of kevlar, mylar or any biologically non-reactive polymer.
25
6. An apparatus as in claim 1, wherein the first treatment balloon
includes a plurality of micropores that can be used for delivery of irrigating fluids,
chilling liquids or pharmaceutical agents.

7. An apparatus as in claim 1, wherein said first treatment balloon is capable of being expanded so as to be in proximity of the interior of a stomach, duodenum or organs adjacent thereto.

5 8. An apparatus as in claim 1, wherein said first treatment balloon includes at least one localized receiver that is responsive to the potential of a nerve, impedance, temperature, current or voltage.

9. An apparatus as in claim 1, wherein the second treatment balloon
10 is comprised of mylar, kevlar or any biologically non-reactive polymer.

10. An apparatus as in claim 1, wherein the second treatment balloon includes a plurality of micropores that can be used for delivery of irrigating fluids, chilling liquids or pharmaceutical agents.

15 11. An apparatus as in claim 1, wherein said second treatment balloon is capable of being expanded so as to be in proximity of the walls of a stomach, duodenum or organs adjacent thereto such as a pylorus.

20 12. An apparatus as in claim 1, wherein said second treatment balloon includes at least one localized receiver that is responsive to the potential of a nerve, impedance, temperature, current or voltage.

13. An apparatus as in claim 1, wherein said plurality of electrodes
25 includes a set of needle-like electrodes.

14. An apparatus as in claim 13, wherein said plurality of needle-like electrodes is arced.

30 15. An apparatus as in claim 1, wherein each electrode in said plurality of electrodes includes a thermocouple.

16. An apparatus as in claim 15, wherein the transmission of energy from each electrode is responsive to feedback from said thermocouple.

5 17. An apparatus as in claim 1, wherein said electrodes are disposed to deliver radio frequency energy.

18. An apparatus as in claim 1, wherein said electrodes are disposed to deliver infrared light, microwave, ultrasound, electromagnetic, photodynamic therapy or other forms of energy.

10

19. An apparatus as in claim 1, including a spacer so as to separate said first balloon from said second balloon in such a way that said first balloon delivers energy and liquids to the duodenum and said second balloon delivers energy and substances to a location in the stomach simultaneously or sequentially.

15

20. An apparatus as in claim 1, wherein said lumens conduct liquids to and from a source external to the patient and a targeted portion of the interior of a stomach, duodenum and pylorus.

20

21. An apparatus as in claim 1, wherein said lumens conduct energy from a source external to the patient to a targeted portion of the interior of a stomach, duodenum and pylorus.

25

22. An apparatus for treatment of obesity including a catheter capable of being disposed in a region of the body of a patient, said region being located proximate to a junction between the stomach and the duodenum;

a treatment balloon;

a set of struts;

30

a plurality of electrodes embedded in said set of struts; and a plurality of lumens.

23. An apparatus as in claim 22, wherein said catheter can be disposed proximate to a gastric cardia, greater curvature, collar of helvetius, middle circular stomach muscle layers, longitudinal and circular muscles of the duodenem, 5 the pylorus and other structures in the digestive system.

24. An apparatus as in claim 22, wherein said catheter is disposed to be inserted orally or through a surgical opening.

10 25. An apparatus as in claim 22, wherein the length of said catheter is responsive to the relative age or size of the patient and the manner of insertion.

26. An apparatus as in claim 22, wherein said treatment balloon is comprised of kevlar, mylar, or any biologically non-reactive polymer.

15 27. An apparatus as in claim 22, wherein said treatment balloon includes a plurality of micropores that can be used for delivery of irrigating fluids, chilling liquids or pharmaceutical agents.

20 28. An apparatus as in claim 22, wherein said first treatment balloon is capable of being expanded so as to cause said plurality of struts to be in immediate proximity to the interior of a stomach, duodenum or organs adjacent thereto.

25 29. An apparatus as in claim 22, wherein said set of struts encompass the exterior surface of said treatment balloon in such a way that expansion of said balloon causes outward movement of said struts.

30 30. An apparatus as in claim 22, wherein said electrode at least one localized receiver that is responsive to the potential of a nerve, impedance, temperature, current or voltage.

31. An apparatus as in claim 22, wherein said plurality of electrodes includes a set of needle-like electrodes.

32. An apparatus as in claim 22, wherein said set of needle-like
5 electrodes is arced.

33. An apparatus as in claim 22, wherein each electrode in said plurality of electrodes includes a thermocouple.

10 34. An apparatus as in claim 33, wherein the transmission of energy from each electrode is responsive to feedback from said thermocouple.

15 35. An apparatus as in claim 22, wherein said electrodes are disposed to deliver radio frequency energy.

36. An apparatus as in claim 22, wherein said electrodes are disposed to deliver infrared light, microwave, ultrasound, electromagnetic, photodynamic therapy or other forms of therapeutic energy.

20 37. An apparatus as in claim 22, wherein said lumens transport liquids to and from a source external to the patient and an interior surface of a stomach or duodenum, pylorus or associated structure.

25 38. An apparatus as in claim 22, wherein said lumens conduct energy from a source external to the patient to a targeted portion of the interior of a stomach, duodenum, pylorus or associated structure.

30 39. A method for treatment of obesity, including steps for inserting a catheter into the stomach of a patient; identifying particular nervous tissue and other structures within the stomach and associated structures;

inflating a first treatment balloon;
inflating a second treatment balloon;
deploying at least one electrode in a tissue.

5 40. A method as in claim 39, wherein said step of inserting can be performed orally or through a surgical opening.

10 41. A method as in claim 39, wherein said step of identifying nervous tissue is performed by visual inspection, measurement of nervous potential or impedance or by other means.

15 42. A method as in claim 39, wherein said step of inflating a first treatment balloon includes inflating said balloon with a chilled liquid, an irrigating liquid or a pharmaceutical agent.

20 43. A method as in claim 39, including the step for delivering said chilled liquid, said irrigating fluid or said pharmaceutical agent to a tissue included in said stomach or duodenum through micropores in said first balloon.

25 44. A method as in claim 39, wherein said step of inflating a second treatment balloon includes inflating said second treatment balloon with a chilled liquid, an irrigating liquid or a pharmaceutical agent.

30 45. A method as in claim 44, including the step of delivering said chilled liquid, said irrigating fluid or said pharmaceutical agent to a tissue included in said stomach or duodenum through micropores in said second balloon.

35 46. A method as in claim 39, wherein the step for deploying at least one electrode includes steps for

creating thermal or other lesions in a stomach, duodenum, pyloris or associated structures.

47. A method as in claim 39, wherein the step for deploying at least
5 one electrode includes steps for
stopping or starting the flow of energy into a tissue through at least one
electrode in response to feedback from a thermocouple or other sensor.

48. A method as in claim 39, wherein the step for deploying at least
10 one electrode includes steps for
ablating a nerve so as to inhibit the relaxation of a stomach
muscle.

49. A method as in claim 39, wherein the step for deploying at least
one electrode includes the steps for
15 delivering microwave, radio frequency, laser, infrared, ultrasound or
other therapeutic energy to the interior of a stomach, duodenum or pylorus.

50. A method for treatment of obesity, including steps for
inserting a catheter into the stomach of a patient;
20 identifying particular nervous tissue and other structures within
the stomach and associated structures;
inflating a treatment balloon in such a way that at least one strut
is positioned relatively proximate to the interior wall of a stomach or a duodenum
and;
25 deploying at least one electrodes in a tissue.

51. A method as in claim 50, wherein said step of inserting can be
performed orally or through a surgical opening.

52. A method as in claim 50, wherein said step of identifying nervous tissue is performed by visual inspection, measurement of nervous potential or impedance or by other means.

5 53. A method as in claim 50, wherein said step of inflating a treatment balloon includes inflating said balloon with a chilled liquid, an irrigating liquid or a pharmaceutical agent.

10 54. A method as in claim 50, including the step for delivering said chilled liquid, said irrigating fluid or said pharmaceutical agent to a tissue included in said stomach or duodenum through micropores in said treatment balloon.

15 55. A method as in claim 50, wherein the step for deploying at least one electrode includes steps for creating thermal or other lesions in a stomach, duodenum, pylorus or associated structures.


20 56. A method as in claim 50, wherein the step for deploying at least one electrode includes steps for stopping or starting the flow of energy into a tissue through at least one electrode in response to feedback from a thermocouple or other sensor.

25 57. A method as in claim 50, wherein the step for deploying at least one electrode includes steps for ablating a nerve so as to inhibit the relaxation of a stomach muscle.


58. A method as in claim 50, wherein the step for deploying at least one electrode includes the steps for

delivering microwave, radio frequency, laser, infrared, ultrasound or other therapeutic energy to the interior of a stomach, duodenum, pylorus or associated structure.


1/5

FIGURE 1


2/5

FIGURE 2


3/5

FIGURE 3

4/5

FIGURE 4 (PART A)

5/5

FIGURE 4 (PART B)

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 00/13703

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61F5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F A61N A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 263 480 A (WERNICKE JOACHIM F ET AL) 23 November 1993 (1993-11-23) claims; figures ----	1,22
A	EP 0 334 086 A (ABBOTT LAB) 27 September 1989 (1989-09-27) ----	
A	US 5 836 994 A (BOURGEOIS IVAN) 17 November 1998 (1998-11-17) ----	
A	EP 0 571 938 A (CIGAINA VALERIO) 1 December 1993 (1993-12-01) ----	
A	US 5 540 734 A (ZABARA JACOB) 30 July 1996 (1996-07-30) ----	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 September 2000	26/09/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Sánchez y Sánchez, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Application No

PCT/US 00/13703

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5263480 A	23-11-1993	US 5188104 A		23-02-1993
		AU 657736 B		23-03-1995
		AU 1346992 A		07-09-1992
		CA 2100872 A		02-08-1992
		DE 69229499 D		05-08-1999
		DE 69229499 T		04-05-2000
		EP 0569522 A		18-11-1993
		WO 9213592 A		20-08-1992
EP 0334086 A	27-09-1989	US 4921481 A		01-05-1990
		AT 83648 T		15-01-1993
		AU 3021389 A		28-09-1989
		CA 1326264 A		18-01-1994
		DE 68903973 D		04-02-1993
		DE 68903973 T		19-05-1993
		ES 2037295 T		16-06-1993
		JP 1284253 A		15-11-1989
		JP 2795882 B		10-09-1998
		KR 9709720 B		17-06-1997
US 5836994 A	17-11-1998	AU 6796798 A		24-11-1998
		WO 9848890 A		05-11-1998
		US 5995872 A		30-11-1999
EP 0571938 A	01-12-1993	IT 1260485 B		09-04-1996
		DE 69324625 D		02-06-1999
		DE 69324625 T		04-11-1999
		ES 2132149 T		16-08-1999
		US 5423872 A		13-06-1995
US 5540734 A	30-07-1996	JP 8229141 A		10-09-1996